Zai Lab Limited (HKG:9688)
24.18
+1.14 (4.95%)
Sep 5, 2025, 4:08 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $109.98M USD in the quarter ending June 30, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $427.80M, up 32.56% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$427.80M
Revenue Growth
+32.56%
P/S Ratio
7.75
Revenue / Employee
$228.89K
Employees
1,869
Market Cap
26.04B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
WuXi Biologics | 21.98B |
Akeso | 2.75B |
CSPC Pharmaceutical Group | 28.49B |
Zai Lab News
- 2 days ago - Amgen dips after trial update for Zai Lab partnered gastric cancer therapy - Seeking Alpha
- 3 days ago - Zai Lab Ltd (ZLAB) Secures Approval for TIVDAK in Hong Kong | ZLAB stock news - GuruFocus
- 3 days ago - Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical ... - GuruFocus
- 3 days ago - Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong - Business Wire
- 8 days ago - Zai Lab Announces Participation in Investor Conferences in September 2025 - Business Wire
- 17 days ago - Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer - Business Wire
- 23 days ago - Zai Lab Establishes Oncology Scientific Advisory Board - Business Wire
- 4 weeks ago - Zai Lab reaffirms $560M-$590M 2025 revenue target as VYVGART and pipeline drive growth - Seeking Alpha